Navigation Links
Argos Therapeutics Announces Additional $17.5 Million Of Series E Financing Bringing Total Commitment To $60 Million

DURHAM, N.C., Nov. 20, 2013 /PRNewswire/ -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that on November 4, 2013, the Company increased the size of its previously announced Series E financing by $17.5 million, bringing the total amount of committed funds from $42.5 million to $60 million.

In August 2013, Argos announced the closing of a $42.5 million Series E financing.  The additional $17.5 million investment represents additional commitments from current Argos investors and one new investor. The funds from the Series E financing will be used to support the Company's ongoing ADAPT pivotal Phase 3 clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC). 

"This funding further strengthens our ability to advance our ADAPT clinical trial.  In addition, the company is now better positioned to consider and pursue a range of options to support our global manufacturing and commercialization plans based on the potential of our Arcelis™ technology platform," said Jeff Abbey, Argos' president and chief executive officer.

About the Arcelis™ Technology Platform
Arcelis is a fully personalized immunotherapy technology that captures mutated and variant antigens that are specific to each patient's disease. It is designed to overcome immunosuppression by producing a durable memory T cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to a wide range of different cancers and infectious diseases and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies.

The Arcelis process uses only a small tumor or blood sample and the patient's own dendritic cells, which are collected and optimized following a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient's disease sample to program dendritic cells to target disease antigens. The activated, antigen-loaded dendritic cells are then formulated into the patient's plasma and administered via intradermal injection.

About Argos Therapeutics
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform.  Argos' most advanced product candidate, AGS-003, has initiated a pivotal Phase 3 study for the treatment of mRCC, and the Company recently completed enrollment of its Phase 2b study of AGS-004 for the treatment of HIV. For more information about Argos Therapeutics, visit

SOURCE Argos Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
3. Argos Confirms Improved RNA Amplification Protocol Enhances Quality of Antigen-Specific Immune Response
4. Argos Therapeutics to Present at the Elsevier Therapeutic Area Partnerships Meeting
5. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
6. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
7. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
8. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
9. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
10. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
11. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
Post Your Comments:
(Date:11/29/2015)... and NUREMBERG, Germany , ... meeting, innovation leader Ziehm Imaging invites attendees to experience ... on the market. The highlight on display is Ziehm ... flat-panel technology that provides a 16 cm edge length ... Vision RFD Hybrid Edition, the first fully motorized mobile ...
(Date:11/27/2015)... --> --> ... The potential to save costs, improve treatment quality and ... fully exploited as yet. Here, particular emphasis is placed ... mobile tablet or directly at the patients, bedside. ... ) -->      (Photo: ...
(Date:11/26/2015)... PUNE, India , November ... --> ... / personal emergency response system ... grow steadily for 5 years ... growing region expected to see ...
Breaking Medicine Technology:
(Date:11/30/2015)... DIAMOND BAR, CALIF. (PRWEB) , ... ... ... Technology, Inc. ( ), a leading provider of enterprise Time and ... Certified Partner status in the Microsoft Partner Program with competencies in the ...
(Date:11/30/2015)... Durham, NC (PRWEB) , ... November 30, 2015 ... ... Orthopedic practices in 2016. In 2016, expected coding changes are likely to include ... prolonged service codes. It’s not easy to understand the effects of code changes ...
(Date:11/29/2015)... Metamora, Michigan (PRWEB) , ... ... ... is once again accredited by the American Institute of Ultrasound in Medicine! ... allows practices to demonstrate that they meet or exceed nationally recognized standards ...
(Date:11/29/2015)... PA (PRWEB) , ... November 29, 2015 , ... While ... with kneeling or provide ready access to exercise weights. Fortunately, an inventor from Uniontown, ... for THE TOMMY WALKER to enhance the benefits of a standard walker to improve ...
(Date:11/28/2015)... ... 28, 2015 , ... StatRad , a leading provider ... and Claude Hooton to its board of directors. The announcement comes as the ... Annual Meeting and continues to strategically transform its focus from being a teleradiology ...
Breaking Medicine News(10 mins):